Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Illumina, Inc.. (4/21/16). "Press Release: Illumina Files Patent Infringement Suit in Switzerland against Genoma SA for Infringement of NIPT Patents". San Diego, CA.

Region Region Switzerland
Organisations Organisation Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
  Organisation 2 Genoma S.A. (CH)
  Group Esperite (Group)
Products Product Tranquility® NIPT testing service
  Product 2 IONA® Test (genomic prenatal maternal blood test)
Persons Person Dadswell, Charles (Illumina 201604 SVP + General Counsel)
  Person 2 Chambers, Rebecca (Illumina 201602 Investor Relations)
     


Illumina, Inc. (NASDAQ: ILMN) today announced that it, and its wholly owned subsidiary, Verinata Health, Inc. (together “Illumina”), filed a patent infringement suit against Genoma SA in the Federal Patent Court in Switzerland. Illumina is seeking all available remedies, including damages and injunctive relief.

The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT).

The suit accuses Genoma’s Tranquility® NIPT testing service, including its use of next-generation sequencing to analyze cell-free DNA from a sample of maternal blood. Genoma’s testing facility in Switzerland also services samples collected from its other labs, including those located in Spain and Italy.

“We will continue to monitor activities in the NIPT field and file suits where appropriate to protect our substantial investments in this technology covered by our intellectual property,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.

The Tranquility NIPT service uses the IONA® Test sold by Premaitha Health plc. Illumina previously filed separate suits against Premaitha in the United Kingdom for sale of the IONA Test.


About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


Illumina, Inc.

Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

   
Record changed: 2018-09-19

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top